Psychiatric disorders in the medically ill: spectrum and chronic illness

Overview

Psychiatric disorders are ubiquitous in medical settings and represent a major source of morbidity, functional decline, and healthcare expenditure. The relationship between mental and physical illness is bidirectional and complex: medical illness can directly cause psychiatric syndromes through neurobiological mechanisms, or indirectly through psychological and social consequences of illness; conversely, pre-existing psychiatric disorders influence the onset, course, and outcome of medical conditions. The field of consultation-liaison (C-L) psychiatry, central to psychosomatic medicine, addresses these interactions in both inpatient and outpatient settings. The term "Psychosomatic Medicine" was first used by Felix Deutsch in the early 1920s; the field was formalised with the publication of the journal Psychosomatic Medicine in 1939 and the founding of the American Psychosomatic Society in 1947.

DSM-5-TR organises psychiatric disorders arising in the context of medical illness into several categories: mental disorder due to another medical condition (covering depressive, bipolar, psychotic, anxiety, obsessive-compulsive, catatonic, and personality change syndromes), delirium and major and mild neurocognitive disorders, somatic symptom and related disorders (SSDs), and psychological factors affecting other medical conditions (PFAOMC). Notable DSM-5-TR changes from DSM-IV-TR include: addition of obsessive-compulsive and related disorder due to another medical condition; removal of amnestic disorder and sleep disorder due to another medical condition; specification of depressive or bipolar illness due to another medical condition; and inclusion of factitious disorder and PFAOMC within the SSD chapter. Understanding this spectrum is essential for RANZCP-level practice.

Epidemiology

Psychiatric morbidity is substantially more common in medical settings than in the community:

Key epidemiological findings:

• Depressive disorders occur at more than twice the community rate among general hospital inpatients.
• Delirium affects approximately 20% of general medical inpatients; rates rise to 43-65% in HIV-infected hospitalised patients and are higher post-operatively, in ICU settings, and on a background of pre-existing neurocognitive disorder.
• Substance use disorders are two to three times more prevalent in hospitalised patients than in community samples.
• Anxiety disorders are the most prevalent psychiatric disorders of childhood, with an estimated lifetime prevalence of 15-20%; prevalence rises to 20-35% in medically ill children.
• Major depressive disorder occurs in approximately 25% of older home-care recipients, 11% of medically hospitalised older adults, and up to 48% of those in long-term care.
• Among older adults in primary care, approximately 30% have at least one active psychiatric diagnosis; 10-15% have clinically significant depressive syndromes (major depression, dysthymia, or minor depression); 5-10% have dementia; and 2-5% have alcohol use disorder or psychosis.
• Bipolar disorder in people aged over 60 accounts for approximately 25% of the total bipolar disease burden; rates across clinical settings range from 3% in nursing home residents to up to 17% in emergency psychiatric settings.
• Among medically ill children, depression prevalence is two to three times that of healthy peers in those with diabetes, 16.3% vs 8.6% in youths with asthma, and approximately five times the general paediatric rate in those with complex partial or absence epilepsy.

Comorbid psychiatric illness consistently increases length of inpatient stay, rehospitalisation rates, and overall healthcare costs.

Aetiology and Pathophysiology

Mechanisms of Psychiatric Disorder in Medical Illness

Three broad causal frameworks operate, often simultaneously:

A fourth pathway, chance co-occurrence, should also be recognised, given that both psychiatric and medical disorders are individually common.

Additional pathophysiological mechanisms include:

• Neuroinflammation: Proinflammatory cytokines (interleukin-6, TNF-α) modulate monoaminergic and glutamatergic neurotransmission, contributing to the "sickness behaviour" phenotype (anhedonia, fatigue, psychomotor slowing, cognitive impairment).
• HPA axis dysregulation: Sustained hypercortisolaemia impairs hippocampal neurogenesis and worsens mood and cognition.
• Metabolic and endocrine disruption: Diabetes is bidirectionally linked to depression via glycaemic variability and inflammatory mediators; subclinical hypothyroidism increases depression risk more than fourfold.
• Neuroanatomical vulnerability: Subcortical cerebrovascular disease disrupts fronto-striato-limbic circuits subserving mood regulation (vascular depression model).
• Pre-morbid psychiatric vulnerability: Prior psychiatric history is the strongest predictor of psychiatric disorder following medical illness.
• Adverse social determinants: Homelessness, poverty, financial and nutritional insecurity substantially compound psychiatric and medical risk.

Clinical Features and DSM-5-TR Classification

Categories of Psychiatric Disorder in Medical Settings

Key DSM-5 SSD changes: The requirement that somatic symptoms be medically unexplained has been removed. Pain disorder has been deleted and is subsumed under SSD. Body dysmorphic disorder has been moved to the OCD chapter. Factitious disorder and PFAOMC are now included within the SSD chapter.

Distinguishing Medical from Primary Psychiatric Syndromes

Depressive symptoms in a hospitalised patient may reflect:

• Adjustment disorder
• Demoralization (not a DSM-5-TR diagnosis; differs from MDD by preserved hedonic capacity and future orientation)
• Medication side effects
• Delirium (particularly hypoactive subtype, frequently misdiagnosed as depression)
• Substance withdrawal
• Major depressive disorder (pre-existing or incident)
• Mental disorder due to another medical condition

Symptoms such as hopelessness, pervasive anhedonia, guilt, and severe insomnia are more diagnostically specific for a primary depressive disorder than somatic symptoms (fatigue, anorexia, weight loss) that may be attributable to the medical illness itself.

Assessment

General Principles

Assessment in medical settings requires integration of psychiatric, medical, and psychosocial data. The clinician must:

1. Be familiar with the medical condition, its treatment, and expected symptom course.
2. Distinguish normal emotional responses to illness from psychiatric disorder.
3. Recognise that medical symptoms (fatigue, poor appetite, sleep disturbance) may confound psychiatric rating scales.
4. Explore the patient's explanatory model, fears, and coping resources.
5. Assess capacity for consent and safety, including suicidality.
6. Evaluate and manage delirium, dementia, and psychiatric disorders due to medical illness.
7. Assess managing suicidality and other high-risk behaviour in the medical setting.

Validated Rating Scales

Differential Diagnosis

The differential for new psychiatric symptoms in a medically ill patient should always include:

• Delirium (must be excluded first; hypoactive subtype often misidentified as depression)
• Primary psychiatric disorder (pre-existing or first episode coinciding with medical illness)
• Mental disorder due to another medical condition (direct pathophysiological cause, see Box 22.3 conditions below)
• Medication-induced disorder (steroids, opioids, antihypertensives, chemotherapy agents, immunosuppressants)
• Substance use or withdrawal (alcohol, opioids, benzodiazepines)
• SSD or Illness Anxiety Disorder (amplification of medically explained or unexplained symptoms)
• Demoralization (reactive, not a DSM-5-TR disorder per se, but prognostically important)
• Grief (expected response to losses associated with illness)

Medical Conditions Causing Psychiatric Disorder Directly

Impact of Psychiatric Comorbidity on Medical Outcomes

Management

General Principles

Management is guided by the aetiology (biological, psychological, social) of the psychiatric presentation and requires close collaboration with the treating medical team. Goals of psychosocial intervention are determined by disease onset, course, prognosis, and the patient's coping skills and support network. Collaborative care models, where psychiatric and medical care are coordinated, demonstrate the strongest evidence base and are associated with substantially reduced treatment costs and shorter inpatient stays.

Pharmacological

Key pharmacological principles:

• Start low, go slow, especially in older adults and those with organ impairment.
• Adjust dosing for renal and hepatic clearance.
• Monitor for drug-drug interactions (polypharmacy is common).
• Minimise anticholinergic burden, particularly in older adults.
• In delirium, non-pharmacological approaches are first-line; low-dose antipsychotics may be used for severe agitation but do not improve overall delirium outcomes and should not be used routinely.

Psychological Interventions

Evidence supports a range of psychotherapeutic approaches adapted to the medical context:

Psychosocial intervention goals shift across the disease trajectory: early illness may focus on adjustment and adherence; advanced illness on existential concerns, comfort, and dignity. Every major psychosocial modality, dynamic, supportive, CBT, has been used in C-L psychiatry, delivered in individual, group, and family formats.

Social and Systems-Level Interventions

• Multidisciplinary team collaboration: Liaison with nursing, allied health, social work, chaplaincy, and occupational therapy is central to C-L psychiatric care.
• Peer support programs: Useful in cancer survivorship, cardiac rehabilitation, and chronic disease management.
• Carer support and psychoeducation: Reduces caregiver burden and institutionalisation in neurodegenerative conditions.
• Addressing social determinants: Financial insecurity, housing instability, and social isolation compound psychiatric and medical morbidity; social work liaison and community referral are core.
• Hospital-based delirium prevention programs (e.g. HELP, Hospital Elder Life Program): Multicomponent interventions addressing orientation, hydration, sleep, mobility, and sensory impairment have strong evidence for reducing delirium incidence.
• Collaborative care models: Integration of mental health services within primary care and specialist medical settings; demonstrated efficacy in diabetes, cardiac disease, and cancer with evidence of considerably reduced treatment costs, primarily through shorter inpatient stays.

Prognosis

• Comorbid psychiatric disorder consistently worsens medical prognosis: greater functional decline, higher mortality (particularly in cardiac disease and HIV), increased hospitalisation, and poorer treatment adherence.
• Effective treatment of comorbid psychiatric illness improves medical outcomes, most clearly demonstrated for depression in ischaemic heart disease, diabetes, and stroke.
• Delirium is associated with increased mortality, prolonged hospitalisation, accelerated cognitive decline (especially on a background of dementia), and higher institutionalisation rates. Hospitalised patients with delirium are significantly less likely to improve in function compared to those without delirium, even after controlling for medical illness severity.
• Untreated depression in medically ill older adults increases all-cause mortality, including suicide. Caucasian men aged over 85 are at the highest risk for completed suicide in the United States, primarily due to firearm use; many visit primary care providers in the weeks prior to a suicide attempt, highlighting the importance of recognition in that setting.

Special Populations

Older Adults

• Psychiatric disorder in older adults is frequently underdiagnosed because symptoms are attributed to normal ageing, social loss, or the medical condition itself, contributing to therapeutic nihilism in both patients and clinicians.
• Loss of physiological reserve with ageing narrows the margin of medication safety and increases vulnerability to delirium, falls, and functional decompensation.
• Depression is the most common psychiatric disorder in medically ill older adults; prevalence is highest in long-term care (up to 48%).
• Subclinical hypothyroidism increases the risk of depression more than fourfold; approximately one-third of patients develop depression within a year after myocardial infarction.
• Antipsychotics in older adults with dementia carry increased risk of stroke and mortality, prescribing should be judicious with regular review.
• New collaborative care models, integrating psychiatry with primary care and specialist physicians, are recommended for older adult populations.

Children and Adolescents

• Medically ill children have elevated rates of anxiety (20-35%) and depression (2-5 times community rates, condition-dependent).
• Developmental considerations affect presentation: younger children may regress behaviourally; pain assessment tools must be age-appropriate (e.g. face-based scales for pre-teens who are regressed).
• Suicidal ideation is increased in children with epilepsy and in adult survivors of childhood cancer; regular, nuanced clinical assessment is necessary given the absence of validated paediatric medically ill suicide screening tools.
• Treatable psychiatric disorders should not exclude terminally ill children from life-saving medical interventions.
• CBT-based approaches have well-established efficacy for procedure-related distress; evidence for non-procedure-related anxiety and depression is more limited but informed by general child and adolescent psychiatry literature.

Pregnancy

• Medical illness during pregnancy (e.g. gestational diabetes, pre-eclampsia, hyperemesis gravidarum) confers additional psychiatric risk.
• The risk-benefit framework for psychotropic prescribing in pregnancy requires careful individualised analysis; untreated psychiatric illness in pregnancy also carries fetal and maternal risk.
• RANZCP and NHMRC guidance should inform decisions about continuation versus cessation of psychiatric medication.

Medicolegal and Ethical Considerations

• Capacity assessment is a core C-L psychiatry function. Capacity is decision-specific and time-specific; the standard requires ability to understand information, retain it, weigh it in the balance, and communicate a decision. Delirium, cognitive impairment, pain, and distress may all affect capacity.
• Informed consent in the context of cognitive impairment: if capacity is lacking, substitute decision-making frameworks apply under relevant state and territory Mental Health Acts and Guardianship legislation.
• Advance care planning: Psychiatrists in C-L settings contribute to discussions about advance directives and goals of care, particularly in palliative contexts.
• Confidentiality: Liaison with the treating medical team must be balanced against the patient's right to privacy; disclosure should occur with the patient's knowledge where possible.
• Non-adherence and refusal of treatment: Patients with psychiatric comorbidity have higher rates of treatment non-adherence; anxiety and depression are recognised risk factors for non-compliance with medical treatment. Involuntary treatment of medical conditions is governed by separate legal frameworks from psychiatric involuntary treatment legislation.
• Resource equity: Integration of mental health care within general health settings is supported by RANZCP Position Statements; access and reimbursement for psychiatric services in medical settings remain significantly limited in many healthcare systems.

Sources

• DSM-5-TR (American Psychiatric Association)
• RANZCP Clinical Practice Guidelines
• NHMRC clinical practice guidelines